WO2001013949A2 - Medizinisches präparat zur behandlung von arthrose, arthritis und anderen rheumatischen gelenkerkrankungen - Google Patents
Medizinisches präparat zur behandlung von arthrose, arthritis und anderen rheumatischen gelenkerkrankungen Download PDFInfo
- Publication number
- WO2001013949A2 WO2001013949A2 PCT/DE2000/002720 DE0002720W WO0113949A2 WO 2001013949 A2 WO2001013949 A2 WO 2001013949A2 DE 0002720 W DE0002720 W DE 0002720W WO 0113949 A2 WO0113949 A2 WO 0113949A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- medical preparation
- preparation according
- radionuclides
- magnetic field
- shell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention relates to a preparation for the treatment of arthrosis, arthritis and other rheumatic joint diseases, consisting of a suspension of magnetized particles provided with a coating, which generate heat in the affected joint by applying an alternating magnetic field.
- systemic pharmacotherapy with analgesics and non-steroidal anti-inflammatory drugs and cortisone are used to treat chronically painful disorders of the supportive and musculoskeletal system, such as arthritis, arthrosis and rheumatic diseases, which are associated with permanent movement restrictions one does not fight the causes of the disease and is also associated with undesirable side effects.
- the radiosynovorthesis, stabilized isotopes with a range of only a few millimeters are injected into the joint in question in order to combat the pathological growth of the inner joint skin in order to damage the cells of the inner joint skin by radiation and thereby the inflammation process curb.
- radiosynoviothesis presupposes the phagocytosis activity of the macrophages which are increasingly present in the joint fluid due to the inflammation, but which increase with increasing age of the Patients decreases, so that the successful use of the radiosynoviorthesis is limited.
- the sick patient is given intravenous colloidal suspensions of magnetic, paramagnetic or diamagnetic particles in the form of Fe 2 0 3 or FeOOH in the size of less than 1 micrometer, which are coated with dextran, metalloporphyrmene and inorganic and organic metal compounds are provided as substituents in the iron core.
- the application of an alternating magnetic field is said to bring about an energy supply in the diseased region, it being unclear how the coated iron oxide particles are to reach the diseased area.
- Colloidal suspensions based on iron oxide particles coated in this way are unable to decisively suppress the inflammatory processes in arthritis, arthrosis and other rheumatic joint diseases.
- the huiformig injected in the form of a magnetic fluid ⁇ tables in the tumor tissue On the one hand, particles are well distributed in the tumor tissue due to their formation described above and, on the other hand, are also well introduced into the interior of the tumor cells. After applying an alternating magnetic field and the resulting temperatures, successful tumor therapy by hyperthermia is possible due to the good distribution of the nanoscale particles.
- the known nanoscale particles are not intended for the treatment of joint diseases and, in the present form, cannot be used to prevent success.
- the invention is therefore based on the object of specifying a means for the local and systemic treatment of arthrosis, arthritis and other rheumatic joint diseases with which, on the basis of the heat supplied by iron oxide particles in a magnetic alternating field, successful pain control and containment of the inflammation processes in those affected Joints is guaranteed.
- the particles according to a first embodiment of the invention consists of a core containing iron oxide as well as an inner shell surrounding it to form ca- tional groups capable groups and an outer shell of neutral and / or anionic group-containing species are formed and radionuclides and cytotoxic substances are bound to the inner shell.
- the nanoscale particles can also have a single layer and only consist of the core and the inner shell - each in the configuration specified above.
- a suspension of iron oxide formed by a core and two shells nanoscale particles is coupled with these doxorubicin as ebensensitivem cyto- toxic material and beta emitters as radionuclides ⁇ di rectly injected into the joint space to be treated.
- the suspension initially remains there for a certain time without the influence of heat, which is determined pratherapeutically.
- the ⁇ ser period may be between one hour and 72 hours lie.
- the two-shell nanoparticles according to the invention are absorbed by the synovial fluid and migrate into the inflamed synovis.
- Magnetic resonance imaging is first used to check whether the nanoparticles are actually embedded in the synovium and in the adjacent lymph nodes and in normal tissue. If necessary, extravasation is carried out in neighboring areas, which cannot be assumed, however, due to the high phagocytosis rate.
- the relevant area is then exposed to an alternating magnetic field with an excitation frequency between 1 kHz and 100 MHz, the level of which depends on the localization of the disease. While hands and arms are treated with higher frequencies, frequencies up to 500 kHz are sufficient for back complaints or lower joints or joints of the thighs.
- the localized heat becomes effective in the affected joint area and at the same time the radionuclide and the cytotoxic substances, in this case doxorubicin, are activated in order to cope with this triple therapy and due to the high phagocytosis rate and the differential endocytosis Nanoparticles to achieve a therapeutic success that is above the addition of the individual effects.
- doxorubicin cytotoxic substances
- the heat that can be achieved due to the magnetic alternating field acting on the nanoscale particles or the duration of the connection of the magnetic alternating field to achieve Aiming for a certain equilibrium temperature is calculated in advance on the basis of the iron oxide concentration, which is between 0.01 and 50 mg / ml of synovial fluid, and the power absorption, which is typically between 50 and 500 mW / mg of iron.
- the field strength is then reduced in order to keep the temperature at the predetermined level, for example 45 ° C.
- the temperature in the cartilage layer is slightly elevated at about 38 to 40 ° C compared to normal physiological conditions.
- the resulting stimulation of the osteoblasts leads to an improved reconstitution of already degeneratively altered bone edges and cartilage.
- Repeated applications of the alternating magnetic field not only counteract recurrent inflammation after the radioactivity has subsided, but are also used - at an equilibrium temperature between 38 and 41 ° C - to stimulate the osteoblast division activity.
- a local concentration (“magnetic targeting”) of the particles can take place in the treated joint.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00967511A EP1204426B1 (de) | 1999-08-19 | 2000-08-09 | Medizinisches präparat zur behandlung von arthrose, arthritis und anderen rheumatischen gelenkerkrankungen |
DE50011033T DE50011033D1 (de) | 1999-08-19 | 2000-08-09 | Medizinisches präparat zur behandlung von arthrose, arthritis und anderen rheumatischen gelenkerkrankungen |
US10/048,037 US6669623B1 (en) | 1999-08-19 | 2000-08-09 | Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases |
AT00967511T ATE302612T1 (de) | 1999-08-19 | 2000-08-09 | Medizinisches präparat zur behandlung von arthrose, arthritis und anderen rheumatischen gelenkerkrankungen |
JP2001518085A JP2003507434A (ja) | 1999-08-19 | 2000-08-09 | 関節症、関節炎、及び他のリウマチ性関節疾患を治療するための医療用調製物 |
AU77695/00A AU7769500A (en) | 1999-08-19 | 2000-08-09 | Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19940220.5 | 1999-08-19 | ||
DE19940220A DE19940220B4 (de) | 1999-08-19 | 1999-08-19 | Medizinisches Präparat zur Behandlung von Arthrose, Arthritis und anderen rheumatischen Gelenkerkrankungen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001013949A2 true WO2001013949A2 (de) | 2001-03-01 |
WO2001013949A3 WO2001013949A3 (de) | 2001-12-20 |
Family
ID=7919494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2000/002720 WO2001013949A2 (de) | 1999-08-19 | 2000-08-09 | Medizinisches präparat zur behandlung von arthrose, arthritis und anderen rheumatischen gelenkerkrankungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US6669623B1 (de) |
EP (1) | EP1204426B1 (de) |
JP (1) | JP2003507434A (de) |
AT (1) | ATE302612T1 (de) |
AU (1) | AU7769500A (de) |
DE (2) | DE19940220B4 (de) |
ES (1) | ES2249297T3 (de) |
WO (1) | WO2001013949A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003022308A2 (en) * | 2001-09-13 | 2003-03-20 | Scientific Generics Limited | Therapeutic insert and therapeutic method |
WO2011128896A1 (en) * | 2010-04-12 | 2011-10-20 | Ramot At Tel-Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
WO2012119775A1 (de) | 2011-03-10 | 2012-09-13 | Magforce Ag | Computergestütztes simulationswerkzeug zur unterstützung bei der planung einer thermotherapie |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7951061B2 (en) * | 2001-07-25 | 2011-05-31 | Allan Foreman | Devices for targeted delivery of thermotherapy, and methods related thereto |
US7731648B2 (en) * | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
EP1481020A2 (de) * | 2002-02-04 | 2004-12-01 | Nanophase Technologies Corporation | Stabile dispersionen von nanoteilchen in wässrigen medien |
DE102005039579B4 (de) * | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
US20080281386A1 (en) * | 2007-05-09 | 2008-11-13 | Tessaron Medical, Inc. | Systems and methods for treating body tissue |
US20080281318A1 (en) * | 2007-05-09 | 2008-11-13 | Tessaron Medical, Inc. | Systems and methods for inductive heat treatment of body tissue |
US20090157069A1 (en) * | 2007-12-06 | 2009-06-18 | Curtis Tom | Systems and methods for thermal treatment of body tissue |
DE102009058650A1 (de) | 2009-12-16 | 2011-06-22 | Leibniz-Institut für Neue Materialien gemeinnützige GmbH, 66123 | Magnetische Kompositpartikel |
KR101513841B1 (ko) | 2011-08-10 | 2015-04-24 | 매그포스 아게 | 응집성의 자성 알콕시실란-코팅된 나노입자 |
DE102012213839B4 (de) * | 2012-08-03 | 2017-06-14 | Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. | Verfahren zur kontrollierten Bewegung von Objekten in flüssigen Medien |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
US5149319A (en) * | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
DE19726282A1 (de) * | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4303636A (en) * | 1974-08-20 | 1981-12-01 | Gordon Robert T | Cancer treatment |
US4590922A (en) * | 1983-08-19 | 1986-05-27 | Gordon Robert T | Use of ferromagnetic, paramagnetic and diamagnetic particles in the treatment of infectious diseases |
US5655546A (en) * | 1995-06-07 | 1997-08-12 | Halpern; Alan A. | Method for cartilage repair |
DE19716732C2 (de) * | 1997-03-07 | 1999-03-25 | Max Delbrueck Centrum | Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung |
-
1999
- 1999-08-19 DE DE19940220A patent/DE19940220B4/de not_active Expired - Fee Related
-
2000
- 2000-08-09 AU AU77695/00A patent/AU7769500A/en not_active Abandoned
- 2000-08-09 EP EP00967511A patent/EP1204426B1/de not_active Expired - Lifetime
- 2000-08-09 AT AT00967511T patent/ATE302612T1/de active
- 2000-08-09 US US10/048,037 patent/US6669623B1/en not_active Expired - Fee Related
- 2000-08-09 DE DE50011033T patent/DE50011033D1/de not_active Expired - Lifetime
- 2000-08-09 ES ES00967511T patent/ES2249297T3/es not_active Expired - Lifetime
- 2000-08-09 WO PCT/DE2000/002720 patent/WO2001013949A2/de active IP Right Grant
- 2000-08-09 JP JP2001518085A patent/JP2003507434A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
US5149319A (en) * | 1990-09-11 | 1992-09-22 | Unger Evan C | Methods for providing localized therapeutic heat to biological tissues and fluids |
DE19726282A1 (de) * | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
Non-Patent Citations (2)
Title |
---|
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; MASAI, AKIRA: "Development of Anticancer-Agent-Releasing Microcapsules for Chemotherapy Combined with Embolo- Hyperthermic Therapy." retrieved from STN Database accession no. PREV199598223481 XP002174710 & NIPPON ACTA RADIOLOGICA, (1995) VOL. 55, NO. 1, PP. 50-57., * |
GRADY E.D. ET AL: "Combination of internal radiation therapy and hyperthermia to treat liver cancer." SOUTHERN MEDICAL JOURNAL, (1983) 76/9 (1101-1105). CODEN: SMJOAV, XP001015654 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003022308A2 (en) * | 2001-09-13 | 2003-03-20 | Scientific Generics Limited | Therapeutic insert and therapeutic method |
WO2003022308A3 (en) * | 2001-09-13 | 2003-05-30 | Scient Generics Ltd | Therapeutic insert and therapeutic method |
WO2011128896A1 (en) * | 2010-04-12 | 2011-10-20 | Ramot At Tel-Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
US9492480B2 (en) | 2010-04-12 | 2016-11-15 | Ramot At Tel Aviv University Ltd. | Iron oxide nanoparticles for use in treating non-infectious inflammatory disorders |
WO2012119775A1 (de) | 2011-03-10 | 2012-09-13 | Magforce Ag | Computergestütztes simulationswerkzeug zur unterstützung bei der planung einer thermotherapie |
US8949088B2 (en) | 2011-03-10 | 2015-02-03 | Magforce Ag | Computer-aided simulation tool for providing assistance in the planning of thermotherapy |
US9844680B2 (en) | 2011-03-10 | 2017-12-19 | Magforce Ag | Computer-aided simulation tool for providing assistance in the planning of thermotherapy |
Also Published As
Publication number | Publication date |
---|---|
US6669623B1 (en) | 2003-12-30 |
AU7769500A (en) | 2001-03-19 |
DE19940220B4 (de) | 2007-05-03 |
WO2001013949A3 (de) | 2001-12-20 |
ES2249297T3 (es) | 2006-04-01 |
ATE302612T1 (de) | 2005-09-15 |
DE50011033D1 (de) | 2005-09-29 |
EP1204426A2 (de) | 2002-05-15 |
EP1204426B1 (de) | 2005-08-24 |
JP2003507434A (ja) | 2003-02-25 |
DE19940220A1 (de) | 2001-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60028240T2 (de) | Apparat und verfahren zur verabreichung einer asymmetrischen strahlungsdosis | |
DE69911221T2 (de) | Methode und gerät zur darreichung von therapeutischen mitteln in verbindung mit dem plazieren von radioaktiven körnern | |
WO2001013949A2 (de) | Medizinisches präparat zur behandlung von arthrose, arthritis und anderen rheumatischen gelenkerkrankungen | |
AT505197B1 (de) | Verfahren zur aktivierung eines photosensibilisators | |
DE60031764T2 (de) | Brachytherapiesamen | |
EP1001811A1 (de) | Nanoskalige teilchen mit einem von mindestens zwei schalen umgebenen eisenoxid-haltigen kern | |
US20150273089A1 (en) | Method of treating cancer | |
DE60210692T2 (de) | Radioaktive Quellen mit niedriger Dämpfung | |
DE69922932T2 (de) | Strahlungsquelle zur endovaskulären Bestrahlung | |
Sun et al. | Reduction of hippocampal-kindled seizure activity in rats by stereotactic radiosurgery | |
DE69930568T2 (de) | Strahlungsquelle zur endovaskulären Bestrahlung | |
EP0855196A1 (de) | Defibrillationselektrode | |
DE60222190T2 (de) | Streifenförmige Quellenanordnung zur intravaskulären Radiotherapie | |
DE602004011253T2 (de) | Brachytherapie-gerät | |
DE2828941C2 (de) | ||
Kubota et al. | Effects of neuromodulation with sacral magnetic stimulation for intractable bowel or bladder dysfunction in postoperative patients with anorectal malformation: a preliminary report | |
DE69830744T2 (de) | Vorrichtung zur steuerung der verstärkung der photonenstrahlungsdosis | |
DE3227506A1 (de) | Medizinisch therapeutisches band oder reifen | |
WO1997025062A2 (de) | Magnetische substanz zur lokalen hyperthermischen behandlung vorwiegend kleiner tumore | |
EP0993319A1 (de) | Katheter oder gefässstütze mit strahlensensibilisator und verfahren zur herstellung | |
Jürgens et al. | Neuromodulation in primary headache in the year 2019: is it still up-to-date? New data on invasive and non-invasive neuromodulation in migraine and cluster headaches | |
DE102018119745A1 (de) | Patch mit aktiven Inhaltsstoffen | |
EP2497526B1 (de) | Implantierbare Elektrodenleitung | |
DE4209844C2 (de) | Radiothermotherapieapplikator | |
Svitra et al. | Proton beam irradiation for treatment of experimental human retinoblastoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000967511 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10048037 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000967511 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000967511 Country of ref document: EP |